May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
"Melanoma Inhibitory Activity" (MIA): A Serological Marker for Metastatic Uveal Melanoma
Author Affiliations & Notes
  • U. C. Schaller
    Dept Ophthalmology, University of Munich LMU, Munich, Germany
  • I. W. Reininger
    Dept Ophthalmology, University of Munich LMU, Munich, Germany
  • Rü. Hein
    Dept Dermatology, Technical University of Munich, Munich, Germany
  • A. J. Mueller
    Dept Ophthalmology, General Hospital Augsburg, Augsburg, Germany
  • A. Kampik
    Dept Ophthalmology, University of Munich LMU, Munich, Germany
  • Footnotes
    Commercial Relationships U.C. Schaller, None; I.W. Reininger, None; R. Hein, None; A.J. Mueller, None; A. Kampik, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4789. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      U. C. Schaller, I. W. Reininger, Rü. Hein, A. J. Mueller, A. Kampik; "Melanoma Inhibitory Activity" (MIA): A Serological Marker for Metastatic Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4789.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: Uveal melanomas typically metastasize to the liver. A sensitive and specific serological marker for metastatic disease would be of great value. The small globular protein "melanoma inhibitory activity" (MIA) is established as a marker for cutaneous melanoma. This study was performed to evaluate MIA as potential serological marker for early detection of metastatic disease in uveal melanoma.

Methods:: In a prospective study we collected serum samples of 390 patients with uveal melanoma. Serum samples were analysed by using a one-step enzyme-linked immunosorbent assay (ELISA) to quantify the MIA serum levels. All patients underwent also standardized A-scan echography to measure the maximum tumor height.

Results:: 31 (7.9 %) patients had proven metastatic disease. The mean serum concentration of MIA in these patients was 17.22 ng/ml, whereas in the 359 patients without metastasis, 6.74 ng/ml (p < 0.001). Sixteen of the 31 patients presented with metastatic disease during follow-up. These patients showed a MIA of 6.49 ng/ml before and of 17.44 ng/ml after the development of metastasis (p = 0.001). Comparing different apical tumor thickness to MIA serum concentrations in patients without metastasis, no significant correlation was found. A correlation between local therapy and MIA serum concentrations could neither be seen.

Conclusions:: The statistically highly significant elevation of MIA serum levels in patients with metastatic disease from melanoma suggests a promising role as a serum marker for monitoring these patients.

Keywords: melanoma • oncology • tumors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.